Epstein Files Search

EFTA01100261Set 9

2016-02-2939p20,086w

Catalysts The key upcoming catalysts for Editas include updates to the interference proceeding, updated preclinical data at the ASGCT conference in May and an IND filing on its first clinical ... could have an impact on Editas. Exhibit 6: Editas Catalyst Calendar Milestones Timing Updated preclinical data at ASGCT 2016 May 4-7, 2016 Potential new business development 2016 Potential interference ... vivo and ex vivo delivery through modalities including viral vectors, nanoparticles, and electroporation. Preclinical data for both ex vivo and in vivo genome editing has provided encouraging early results

https://www.justice.gov/epstein/files/DataSet%209/EFTA01100261.pdf

EFTA02295528Set 11

49p3,041w

failure is "an unmet medical need". • We have the intellectual property. • We have compelling preclinical data. • We can make a compelling pharmco-economic case for reimbursement. We can save more ... EFTA_R1_01138842 EFTA02295568 ConcentRx Investment Thesis • Poised to quickly file IND with unprecedented preclinical data in an area of high unmet medical need - ovarian cancer. • Both components

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02295528.pdf

EFTA02683561Set 11

2014-09-249p2,522w

pharmaceutical industry. Nat would be entirely capable of completing this project and delivering the preclinical data that can be evaluated by potential pharma partners for the deve lopment ... behaviors in mice. Completion of these studies will result in a complete package of preclinical data that can be evaluated by potential pharmaceutical partners for the development of new drugs

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02683561.pdf

EFTA01127977Set 9

2014-09-249p2,510w

industry. Nat would be entirely capable of completing this project and deliv ering the preclinical data that can be evaluated by potential pharma partners for the deve lopment ... behaviors in mice. Completion of these studies will result in a complete package of preclinical data that can be evaluated by potential pharmaceutical partners for the development of new drugs

https://www.justice.gov/epstein/files/DataSet%209/EFTA01127977.pdf

EFTA00506107Set 9

49p3,212w

failure is "an unmet medical need". ▪ We have the intellectual property. • We have compelling preclinical data. • We can make a compelling pharmco-economic case for reimbursement. We can save more ... DACART CAPITAL LLC.L' EFTA00506147 ConcentRx Investment Thesis • Poised to quickly file IND with unprecedented preclinical data in an area of high unmet medical need - ovarian cancer. ▪ Both components

https://www.justice.gov/epstein/files/DataSet%209/EFTA00506107.pdf

EFTA00596368Set 9

7p1,105w

Data Comparative analysis Rigorous comparative analysis Bioassay Data One comparative bioassay Two comparative assays Preclinical DATA May be waived (I) May be waived (') Rigorous comparative PK study to Rigorous comparative

https://www.justice.gov/epstein/files/DataSet%209/EFTA00596368.pdf

EFTA00753599Set 9

7p1,105w

Data Comparative analysis Rigorous comparative analysis Bioassay Data One comparative bioassay Two comparative assays Preclinical DATA May be waived (I) May be waived (') Rigorous comparative PK study to Rigorous comparative

https://www.justice.gov/epstein/files/DataSet%209/EFTA00753599.pdf

EFTA01092032Set 9

25p12,760w

either 20 million ADRCs (n=10) or a placebo (n=4). There is solid preclinical data showing efficacy of ADRC in myocardial infarction. In a porcine model, after induction

https://www.justice.gov/epstein/files/DataSet%209/EFTA01092032.pdf

EFTA00506070Set 9

2013-08-2236p3,940w

better Intracellular concentrations and half-lives 5 EFTA00506074 2013-08-22 Strong in vitro & preclinical data provide consistent rationale why EPB-348 is more potent than other antivirals Active Drug

https://www.justice.gov/epstein/files/DataSet%209/EFTA00506070.pdf

EFTA00506157Set 9

46p3,296w

failure is "an unmet medical need". • We have the intellectual property. • We have compelling preclinical data. • We can make a compelling pharmco-economic case for reimbursement. We can save more

https://www.justice.gov/epstein/files/DataSet%209/EFTA00506157.pdf

EFTA00956529Set 9

2013-03-147p5,347w

fact, this is one of the company's we strengths —its ability to create preclinical data sets that derisk the clinical programs in humans. About 30M people

https://www.justice.gov/epstein/files/DataSet%209/EFTA00956529.pdf